Dogwood Therapeutics, Inc. (DWTX): Nasdaq/NYSE listing notice — Virios receives Nasdaq deficiency notice for bid price; requests hearing to seek compliance extension

Dogwood Therapeutics, Inc.

Second Nasdaq letter received May 1, 2024 for failure to maintain $1.00 minimum bid price.
Initial 180-day compliance period expired April 30, 2024; company has requested a hearing to stay delisting.
Plan to regain compliance includes IMC-2 Long-COVID study data from Bateman Horne Center and potential reverse stock split.
Hearing before Nasdaq panel will determine extension; common stock (VIRI) remains listed pending decision.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Dogwood Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price.

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price

Exact text from the filing

May 1, 2024, we received another letter from Nasdaq informing us that our shares had failed to comply with the $1.00 minimum bid price required for continued listing. In accordance with the latest letter and established Nasdaq procedures, we have requested a hearing with Nasdaq, at which, we will seek to extend the period during which we will seek to regain compliance. Our request for such hearing has stayed the delisting of our common stock pending a Nasdaq hearings panel’s (the “Panel”) decision. We intend to present a plan to regain compliance to the Panel that includes a discussion of the

View on SEC.gov

94 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.